89bio reports third quarter 2023 financial results and provides corporate updates

–pegozafermin granted breakthrough therapy designation (btd) for the treatment of nonalcoholic steatohepatitis (nash) with fibrosis–
ETNB Ratings Summary
ETNB Quant Ranking